What is the clinical evidence from this study?

Study design: Review. Population: ischemic cardiomyopathy. Intervention: Myocardial viability testing.

What does this research mean for the field?

Myocardial viability should be reconceptualized as a continuous spectrum focused on scar quantification, as recent trials demonstrate that binary viability status does not predict survival benefit from revascularization in ischemic cardiomyopathy. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

The study aims to reassess the role of myocardial viability testing in guiding revascularization decisions for ischemic cardiomyopathy patients.

July 8, 2026Current Opinion in Cardiology

Viability testing fails to predict survival after revascularization, while scar quantification offers greater prognostic value.

View Full Paper

Ask AI

Bookmark

Why the study?

Does myocardial viability testing improve survival and functional recovery in patients with ischemic cardiomyopathy undergoing revascularization?

Population

Patients with ischemic cardiomyopathy

Design

Review

Key result

Myocardial viability testing does not independently predict survival benefit from revascularization in ischemic cardiomyopathy, whereas scar quantification may offer greater prognostic utility.

Authors

KLKevin Y. Li NDNitish K. Dhingra RPRaumil PatelUniversity Health Network

Discussion

Member takes

Overview

Viability testing may not guide revascularization in ischemic cardiomyopathy; challenges traditional assumptions and leaves open its role with modern therapies.

Key Points

The study aims to reassess the role of myocardial viability testing in guiding revascularization decisions for ischemic cardiomyopathy patients.
Reviewed findings from recent trials including STICH and REVIVED-BCIS2.
Analyzed the impact of viability and scar burden on patient outcomes.
Discussed the implications of imaging techniques like CMR on viability assessment.
CABG was shown to improve long-term survival regardless of viability status (STICH trial).
PCI did not demonstrate a survival benefit in patients with viable myocardium (REVIVED-BCIS2).
Scar burden emerged as a stronger predictor of adverse outcomes than viability presence.

Structured PICO

Does myocardial viability testing improve survival and functional recovery in patients with ischemic cardiomyopathy undergoing revascularization?

Population

Patients with ischemic cardiomyopathy

Exposure

Myocardial viability testing to guide revascularization

Outcome

Survival and functional recovery

This review highlights that contemporary trial data challenges the traditional use of myocardial viability testing to guide revascularization, suggesting a shift towards scar quantification.

Cite This Study

Li et al. (2026) conducted a review in ischemic cardiomyopathy. Myocardial viability testing was evaluated. Myocardial viability testing does not independently predict survival benefit from revascularization in ischemic cardiomyopathy, whereas scar quantification may offer greater prognostic utility.

synapsesocial.com/papers/6a4de835d2ea289ef6282f9f https://doi.org/10.1097/hco.0000000000001329

View Full Paper

Ask AI

Bookmark

July 8, 2026Current Opinion in Cardiology

Viability testing fails to predict survival after revascularization, while scar quantification offers greater prognostic value.

View Full Paper

Ask AI

Bookmark

Why the study?

Does myocardial viability testing improve survival and functional recovery in patients with ischemic cardiomyopathy undergoing revascularization?

Population

Patients with ischemic cardiomyopathy

Design

Review

Key result

Myocardial viability testing does not independently predict survival benefit from revascularization in ischemic cardiomyopathy, whereas scar quantification may offer greater prognostic utility.

Authors

KLKevin Y. Li NDNitish K. Dhingra RPRaumil PatelUniversity Health Network

Discussion

Member takes

Overview

Viability testing may not guide revascularization in ischemic cardiomyopathy; challenges traditional assumptions and leaves open its role with modern therapies.

Key Points

The study aims to reassess the role of myocardial viability testing in guiding revascularization decisions for ischemic cardiomyopathy patients.
Reviewed findings from recent trials including STICH and REVIVED-BCIS2.
Analyzed the impact of viability and scar burden on patient outcomes.
Discussed the implications of imaging techniques like CMR on viability assessment.
CABG was shown to improve long-term survival regardless of viability status (STICH trial).
PCI did not demonstrate a survival benefit in patients with viable myocardium (REVIVED-BCIS2).
Scar burden emerged as a stronger predictor of adverse outcomes than viability presence.

Structured PICO

Does myocardial viability testing improve survival and functional recovery in patients with ischemic cardiomyopathy undergoing revascularization?

Population

Patients with ischemic cardiomyopathy

Exposure

Myocardial viability testing to guide revascularization

Outcome

Survival and functional recovery

This review highlights that contemporary trial data challenges the traditional use of myocardial viability testing to guide revascularization, suggesting a shift towards scar quantification.

Cite This Study

synapsesocial.com/papers/6a4de835d2ea289ef6282f9f https://doi.org/10.1097/hco.0000000000001329

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark